Free Trial
Yun Zhong

Yun Zhong Analyst Performance

Senior Vice President, Equity Research at Wedbush

Yun Zhong is a stock analyst at Wedbush in the medical sector, covering 22 publicly traded companies. Over the past year, Yun Zhong has issued 27 stock ratings, including buy and hold recommendations. While full access to Yun Zhong's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Yun Zhong's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
42 Last 8 Years
Buy Recommendations
90.24% 37 Buy Ratings
Companies Covered
22 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy90.2%37 ratings
Hold9.8%4 ratings
Sell0.0%0 ratings

Out of 41 total stock ratings issued by Yun Zhong at Wedbush, the majority (90.2%) have been Buy recommendations, followed by 9.8% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
22 companies

Yun Zhong, an analyst at Wedbush, currently covers 22 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
22 companies
100.0%

Yun Zhong of Wedbush specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
18 companies
81.8%
MED - DRUGS
2 companies
9.1%
MED - GENERIC DRG
1 company
4.5%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company
4.5%

About Yun Zhong

Yun Zhong, PhD, is a senior research analyst specializing in biotechnology. Before joining Wedbush, he served as a vice president on the biotech team at Jefferies and held senior biotech analyst roles at Janney Montgomery Scott, Berenberg Capital Markets, and BTIG. Yun's expertise spans orphan diseases, genetic medicine, hematology, neuromuscular diseases, and metabolic disorders. His career began at Cowen and Company, followed by a position at SunTrust Robinson Humphrey. Yun earned his PhD in neuroscience and molecular biology from Rockefeller University and holds both an MS and a BS in biophysical engineering from Osaka University in Japan. His strong technical background and genuine interest in the scientific aspects of biotechnology allow him to understand therapeutic mechanisms at a molecular level, providing a more objective and differentiated perspective. Yun is particularly focused on gene therapy and genetic medicine, areas where he remains optimistic about its potential to offer significant advancements in patient care.
Follow on LinkedIn

Yun Zhong's Ratings History at Wedbush

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
CG Oncology, Inc. stock logo
CGON
CG Oncology
5/11/2026Boost Price Target$69.62$80.00Outperform
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
5/6/2026Boost Price Target$99.21$118.00Outperform
Passage Bio, Inc. stock logo
PASG
Passage Bio
4/21/2026Reiterated Rating$6.25$8.00Neutral
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
4/9/2026Reiterated Rating$233.20$273.00Outperform
Rezolute, Inc. stock logo
RZLT
Rezolute
3/25/2026Upgrade$2.69$5.00Outperform
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
3/12/2026Boost Price Target$5.01$10.00Outperform
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
3/6/2026Boost Price Target$13.20$35.00Outperform
MannKind Corporation stock logo
MNKD
MannKind
3/5/2026Lower Price Target$2.95$8.00Outperform
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
3/2/2026Lower Price Target$16.06$29.00Outperform
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2/12/2026Boost Price Target$216.08$273.00Outperform
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1/23/2026Boost Price Target$21.79$34.00Outperform
Rezolute, Inc. stock logo
RZLT
Rezolute
1/8/2026Boost Price Target$2.35$2.00Neutral
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
12/12/2025Boost Price Target$16.75$33.00Outperform
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
12/9/2025Initiated Coverage$21.86$32.00Outperform
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
11/18/2025Reiterated Rating$216.56$220.00Outperform
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
11/11/2025Reiterated Rating$4.12$8.00Outperform
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
11/11/2025Boost Price Target$7.13$20.00Outperform
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
11/6/2025Boost Price Target$15.65$16.00Neutral
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
10/29/2025Initiated Coverage$1.93$8.00Outperform
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
10/28/2025Boost Price Target$75.25$86.00Outperform
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
9/30/2025Lower Price Target$6.24$18.00Outperform
Passage Bio, Inc. stock logo
PASG
Passage Bio
8/13/2025Boost Price Target$5.97$40.00Outperform
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
8/11/2025Initiated Coverage$8.73$28.00Outperform
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
8/8/2025Boost Price Target$183.33$220.00Outperform
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
8/7/2025Lower Price Target$3.40$8.00Outperform
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
5/27/2025Initiated Coverage$2.01$8.00Outperform